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Take home message  
Obstructive and restrictive phenotypes are present from childhood to adulthood but 
without age trends. Established risk factors for airway disease were associated with 
the obstructive phenotype, whereas low BMI was associated with the restrictive. 
 
ABSTRACT  
Background: The prevalences of obstructive and restrictive spirometric phenotypes, 
and their relation to early-life risk factors from childhood to young adulthood remain 
poorly understood. The aim was to explore these phenotypes and associations with 
well-known respiratory risk factors across ages and populations in European 
cohorts. 
  
Methods: We studied 49,334 participants from 14 population-based cohorts in 
different age-groups (=<10, >10-15, >15-20, >20-25 years, and overall, 5-25 years). 
The obstructive phenotype was defined as FEV1/FVC z-score <the lower limit of 
normal (LLN), whereas the restrictive as FEV1/FVC z-score >=LLN, and FVC 
z-score <LLN. 
Results: The prevalence of obstructive and restrictive phenotypes varied from 
3.2-10.9% and 1.8-7.7%, respectively, without clear age trends. A diagnosis of 
asthma (adjusted odds ratio, aOR=2.55 [95% CI=2.14-3.04]), preterm birth 
(aOR=1.84 [1.27-2.66]), maternal smoking during pregnancy (aOR=1.16 
[1.01-1.35]), and family history of asthma (aOR=1.44 [1.25-1.66]) were associated 
with a higher prevalence of obstructive, but not restrictive phenotype across ages 
(5-25 years). A higher current body mass index (BMI) was more often observed in 
those with the obstructive phenotype but less in those with the restrictive (aOR=1.05 
[1.03-1.06] and aOR=0.81 [0.78-0.85], per kg/m
2
 increase in BMI, respectively). 
Current smoking was associated with the obstructive phenotype in participants older 
than 10 years (aOR=1.24 [1.05-1.46]). 
Conclusion: Obstructive and restrictive phenotypes were found to be relatively 
prevalent during childhood, which supports the early origins concept. Several 
well-known respiratory risk factors were associated with obstructive phenotype, 
whereas only low BMI was associated with the restrictive phenotype, suggesting 
different underlying pathobiology of these two phenotypes. 
 
 
Key Words: Asthma, Lung function, Obstructive, Restrictive, Preterm, Smoking. 
  
INTRODUCTION  
Low peak lung function detected by spirometry in early adulthood relates to the 
increased incidence of respiratory, cardiovascular, and metabolic abnormalities, as 
well as premature death [1, 2]. Spirometry allows the identification and 
quantification of the severity of a ventilatory impairment, as well as the first step of 
classification into two main phenotypes, obstructive and restrictive patterns. The 
obstructive phenotype is defined by an lower than expected forced expiratory 
volume in 1 second/forced vital capacity (FEV1/FVC) ratio, and the restrictive 
pattern by an abnormally low FVC with a normal FEV1/FVC ratio (yet 
acknowledging that body plethysmography is needed to diagnose restrictive lung 
disease) [3]. Although both phenotypes are relatively common [4-10] and 
well-studied in adult cohorts [3, 9, 11, 12], to date, no large study has investigated 
their respective prevalence, age dependency, or associated risk factors in the period 
from childhood to young adulthood. The CADSET (Chronic Airway Disease Early 
Stratification) clinical research collaboration launched by the European Respiratory 
Society (ERS) in 2018 [13] offers a unique opportunity to combine individual data 
from multiple cohorts to increase the sample size required to explore these questions. 
In the current study, we collected data from almost 50,000 subjects across 14 
population-based cohorts in Europe in order to report the age-specific prevalence, 
characteristics, and risk factors for spirometric phenotypes from early childhood to 
young adulthood (5 to 25 years of age), using the Global Lung Function Initiative 
(GLI) reference values [14].  
 
METHODS  
Study design and subjects 
Fourteen European population-based cohorts from seven countries were included in 
the current meta-analysis. A total of 49,334 participants were included in the current 
study, and 18,430 of them (from seven cohorts) had repeated lung function 
measurements from 4 to 25 years of age. Details about each cohort and the 
definition of covariates are provided in the online supplement.  
 
Measurements and definitions of outcomes 
Pre-bronchodilator lung function was tested in each cohort according to the 
ATS/ERS spirometry criteria [15]. FEV1, FVC, and FEV1/FVC were converted into 
z-scores according to the equations from the GLI [14] for each cohort separately. 
Although no disease selective cohorts were included, a high heterogeneity in GLI fit 
between age groups and between co orts (see  esults, “The fit of GLI z-scores” and 
Table 1) was observed, and we therefore applied a centering approach to make the 
cohorts more comparable. Centering was performed separately for each cohort and 
age group by subtracting the mean z-score (of FEV1, FVC, and FEV1/FVC, 
respectively) of non-smoking individuals without asthma (where a perfect fit would 
give a mean of 0 z-scores) from each individual z-score lung function variable. 
The diagnostic algorithm of our spirometry phenotypes was based on the lower limit 
of normal (LLN) as the lower fifth percentile of distribution that corresponds to a 
z-score -1.645 (rounded to -1.65 if two decimals were used) and used as follows 
(Table E1): normal lung function was defined as the FEV1/FVC ratio and FVC 
z-scores equal to or higher than LLN. The obstructive phenotype was defined as 
FEV1/FVC ratio z-score lower than LLN, and severity defined according to Quanjer 
et al. as mild, moderate, and severe according to thresholds of FEV1: z-score less 
than LLN but greater or equal than -2, less than -2 but greater or equal than -3, and 
less than -3, respectively [16]. In addition to these, a very mild group was added, 
defined as a FEV1/FVC ratio z-score lower than LLN and FEV1 z-score greater or 
equal than LLN. The restrictive phenotype (“Low F C, non-obstructive”) was 
defined as FEV1/FVC ratio z-score equal to or higher than LLN, and FVC z-score 
lower than LLN. Severity was evaluated as mild, moderate, and severe according to 
two thresholds of FVC: z-score less than LLN but greater or equal than -2, less than 
-2 but greater or equal than -3, and less than -3, respectively [16].  
 
Statistical analysis 
We performed cohort-specific analyses followed by meta-analysis. The associations 
between the cohort-specific prevalence of obstructive and restrictive phenotypes and 
age were tested by Pearson correlation. Comparisons of the prevalence of wheezing 
and asthma between obstructive and restrictive phenotypes and normal lung function 
groups were performed using the Wilcoxon Rank Sum test. Multivariable regression 
models were conducted to identify risk factors of obstructive and restrictive 
phenotypes, and FEV1, FVC, and FEV1/FVC ratio z-scores, respectively. We used 
two models to explore selected potential risk factors. In the first model, three 
well-known early-life respiratory risk factors (asthma family history, maternal 
smoking during pregnancy, and preterm birth (delivery before 37 completed weeks of 
gestation)), and two lifestyle factors (body mass index (BMI) and smoking status) 
were evaluated using logistic (for obstructive and restrictive phenotypes) and linear 
regressions (for z-scores). In the second model, current asthma was added as predictor 
to the models to specifically evaluate the influence of asthma since this is typically 
classified as an obstructive disease. In the meta-analysis of cohort-specific results, we 
combined data from each cohort in age- groups separately 
(=<10, >10-15, >15-20, >20-25 years), as well as overall across ages (5-25 years). For 
those cohorts that had repeated lung function measurements from multiple time points 
(i.e., data from several age groups), regression analysis for each time point was 
performed and included in the relevant age group. Where multiple time points existed 
for a cohort in an age group, only the largest age group was used in the meta-analyses 
(both age-bin specific and overall) to provide estimates from truly independent 
datasets. Heterogeneity was assessed with the Q and the I
2
 statistic. The Q statistic 
was calculated according to the weighted sum of squared differences between 
individual study effects and the pooled effect across studies and is distributed as a 
chi-square statistic with k (number of studies) minus 1 degrees of freedom [17]. The I
2
 
statistic describes the percentage of variation across studies that is due to 
heterogeneity rather than chance [18, 19]. A random-effects model was used to pool 
data if substantial heterogeneity was observed (I
2
 > 50% or P < 0.1 for Q statistic), 
otherwise we used a fixed-effects model. Meta-analyses were performed using the R 




Table 1 illustrates the basic characteristics of the cohorts. Of the fourteen included 
cohorts, seven (ALSPAC, BAMSE, Generation R, INMA, MAAS, PIAMA, 
SEATON) contributed repeated data from early childhood to young adulthood (age 4 
to 25 years). Two, eight, eight, thirteen, and four cohorts contributed results in the 
1-5, >5-10, >10-15, >15-20, >20-25 years age groups, respectively. As the 1-5 age bin 
only contained two cohorts (INMA and SEATON), the 1-5 and >5-10 age groups 
were combined into the <10 age bin in the meta-analysis. Although INMA 
contributed data at 4, 7 and 9 years, only the largest dataset (7 years) was included in 
the meta-analysis in the <10 age bin. 
 
The fit of GLI z-scores 
The fit of GLI z-scores is described for each cohort in non-asthmatic, asymptomatic 
lifelong non-smokers as mean and SD in Table 1. While the overall GLI fit was good 
in many age groups in the cohorts, a high heterogeneity was observed. For six, five, 
and three cohorts’ GLI fit estimates for FEV1, FVC, and FEV1/FVC z-scores, 
respectively, were outside the suggested range using 0.4 as a cut-off [20] (Figure E1). 
Therefore, we proceeded with mean-centered z-scores (as described in the Methods) 
for comparisons of prevalences across cohorts, and for the meta-analyses. While mean 
GLI z-score values varied by cohort and age, the SD was close to 1 in all groups.  
 
















>5-10 6804 8.7 (0.3) 0.04 (1.00) -0.09 (1.02) -0.06 (1.02) -0.02 (1.04) 0.15 (1.02) -0.10 (1.07) 
>15-20 4519 15.5 (0.3) -0.68 (1.29) -0.04 (1.26) -1.02 (1.29) 0.04 (1.25) 0.61 (1.16) -0.14 (1.21) 




>5-10 1832 8.3 (0.5) 0.47 (0.94) -0.06 (0.94) 0.59 (0.90) -0.00 (0.91) -0.27 (0.87) -0.07 (0.89) 
>15-20 2052 16.7 (0.4) 0.06 (0.92) -0.11 (0.94) 0.16 (0.92) -0.01 (0.92) -0.19 (0.93) -0.15 (0.96) 
>20-25 2032 22.5 (0.5) -0.23 (0.85) -0.03 (0.86) -0.12 (0.85) 0.07 (0.85) -0.20 (0.88) -0.15 (0.90) 
Generatio
n R * 
Netherlan
ds 
>5-10 4738 9.8 (0.3) 0.19 (0.93) -0.04 (0.93) 0.21 (0.89) 0.02 (0.92) -0.08 (0.90) -0.01 (0.96) 
>10-15 3869 13.6 (0.4) -0.15 (1.01) -0.06 (0.93) -0.09 (0.98) 0.04 (0.99) -0.13 (0.92) 0.00 (1.02) 
HUNT1 Norway 
>10-15 2705 14.1 (0.6) -0.23 (1.11) -0.02 (1.11) -0.19 (1.10) 0.01 (1.10) -0.07 (1.03) -0.05 (1.03) 
>15-20 5256 17.1 (1.3) -0.12 (1.04) -0.03 (1.04) -0.09 (1.01) 0.02 (1.01) -0.08 (0.98) -0.08 (0.98) 
HUNT3 Norway 
>10-15 2792 14.1 (0.6) 0.01 (1.03) -0.01 (1.03) 0.10 (1.05) 0.04 (1.05) -0.15 (1.02) -0.22 (1.02) 
>15-20 4363 16.9 (1.2) 0.09 (0.99) -0.04 (0.99) 0.19 (1.01) 0.03 (1.01) -0.19 (0.98) -0.09 (0.97) 
INMA * Spain 
1-5 704 4.5 (0.2) -0.59 (1.20) -0.01 (1.21) -0.53 (1.23) 0.01 (1.25) -0.03 (0.95) -0.03 (0.97) 
 >5-10 1277 7.4 (0.6) 0.21 (0.98) -0.01 (0.99) 0.40 (0.95) 0.01 (0.96) -0.34 (0.99) -0.03 (1.00) 
>5-10 476 9.3 (0.9) -0.02 (1.07) -0.03 (1.05) 0.17 (1.04) -0.00 (1.01) -0.21 (0.98) -0.06 (0.95) 
>10-15 988 11.2 (0.6) -0.20 (1.00) -0.01 (1.03) -0.06 (1.03) 0.02 (1.04) -0.25 (0.95) -0.04 (1.01) 
>10-15 266 14.6 (0.2) 0.04 (0.94) -0.04 (0.95) -0.04 (0.98) -0.02 (0.95) 0.13 (0.87) -0.03 (0.90) 




>5-10 980 9.9 (0.3) 0.37 (0.97) -0.04 (0.99) 0.16 (0.88) 0.02 (0.88) 0.33 (0.96) -0.09 (1.01) 
>15-20 836 17.8 (0.6) 0.30 (0.92) -0.15 (0.99) 0.14 (0.85) 0.01 (0.93) 0.22 (1.07) -0.21 (1.11) 
LEAD Austria >5-10 451 8.4 (1.0) 0.46 (1.27) -0.07 (0.99) 0.31 (1.26) 0.10 (0.92) 0.35 (1.17) -0.31 (1.13) 
>10-15 526 12.3 (1.5) 0.01 (1.03) -0.35 (1.02) -0.19 (0.97) -0.14 (0.98) 0.36 (0.95) -0.39 (1.04) 
>15-20 540 17.4 (1.4) -0.05 (1.07) -0.36 (1.01) -0.22 (1.08) -0.11 (0.97) 0.30 (1.08) -0.44 (1.12) 




>15-20 2556 18.9(0.8) -0.42 (0.91) -0.06 (0.92) -0.34 (0.90) 0.03 (0.89) -0.19 (0.98) -0.14 (1.01) 




>5-10 778 8.0 (0.2) 0.15 (0.93) -0.07 (0.10) 0.26 (0.90) 0.00 (0.94) -0.24 (0.89) -0.11 (0.93) 
>10-15 778 11.5 (0.5) -0.12 (0.95) -0.05 (1.00) -0.18 (1.12) 0.05 (1.12) 0.14 (1.03) -0.15 (1.10) 
>15-20 566 16.0 (0.6) -0.26 (0.95) -0.06 (1.05) -0.43 (0.90) 0.03 (0.96) 0.31 (1.02) -0.16 (1.11) 
>15-20 504 19.4 (0.8)  -0.24 (0.87) -0.04 (0.95) -0.40 (0.90) 0.10 (0.90) 0.26 (0.97) -0.24 (1.04) 




>5-10 1058 8.1 (0.3) 0.54 (0.88) -0.05 (0.91) 0.29 (0.88) 0.00 (0.90) 0.42 (1.06) -0.09 (1.09) 
>10-15 1267 12.7 (0.4) -0.56 (0.84) -0.04 (0.86) -0.37 (0.85) -0.01 (0.86) -0.37 (0.87) -0.04 (0.89) 





1-5 446 4.9 (0.2) 0.17 (0.96) -0.03 (0.95) -0.13 (1.05) -0.00 (1.05) 0.08 (0.93) -0.04 (0.95) 
>10-15 430 10.3 (0.2) -0.12 (1.10) -0.06 (1.09) -0.24 (1.04) -0.01 (1.04) 0.15 (0.93) -0.08 (0.96) 
>15-20 534 15.1 (0.3) -0.36 (1.00) -0.04 (1.00) -0.77 (1.02) 0.01 (1.00) 0.83 (1.09) -0.10 (1.13) 
SUS Denmark >15-20 2294 18.9 (1.3) -0.29 (0.90) -0.01 (0.90) -0.33 (0.88) 0.05 (0.88) 0.01 (1.00) -0.09 (1.00) 
Data was shown in mean (standard deviation).  
*: They are longitudinal cohorts with repeated measurement at different age.  
¶: Based on the whole group of participants.  
§: Based on non-asthmatic, asymptomatic lifelong non-smokers. 
 
Prevalence of spirometric phenotypes and association with respiratory 
symptoms   
We used the mean-centred z-scores to explore the prevalence of spirometry 
impairment phenotypes across ages and cohorts. The prevalence of obstructive and 
restrictive phenotypes during early childhood and young adulthood ranged from 3.2 
to 10.9% and 1.8 to 7.7%, respectively (Figure 1A and 1B). There was no overall 
association between age and the prevalence of obstructive and restrictive phenotypes 
(r = 0.14, P = 0.39 and r = - 0.14, P = 0.41, respectively, Figure E2A and E2B). 
Most participants with the obstructive phenotype were classified as having a (very) 
mild impairment, while most participants with the restrictive phenotype were 
classified as having a mild to moderate impairment (Figure 1A and 1B). 
 
Participants with the obstructive phenotype more frequently reported wheezing in 
the previous 12 months and having been diagnosed with asthma when compared to 
participants with normal lung function (Median=26.6%, interquartile range 
(IQR)=16.7 to 36.4% vs.12.5%, IQR=7.9 to 18.1%, P < 0.001, and 29.8%, IQR= 
21.9 to 42.3% vs. 12.3%, IQR=7.1 to 22.5%, P < 0.001, respectively, Figure 2 and 
E3). However, no significant difference in respiratory symptoms between 
participants with the restrictive phenotype and normal lung function was observed 
(12.7%, IQR=7.6 to 18.1% vs.12.5%, IQR=7.9 to 18.1%, P = 0.95, and 10.1%, 
IQR=7.1 to 20.9% vs.12.3%, IQR=7.1 to 22.5%, P = 0.57, respectively, Figures 2 
and E1). In the adjusted regression models, a current diagnosis of asthma was 
strongly associated with the obstructive phenotype (5-25 years age group adjusted 
odds ratio, aOR=2.55, 95% CI: 2.14 to 3.04, Figure 3, for other subgroups see 
Figure E4). No association between a current diagnosis of asthma and the restrictive 
phenotype (Figure E5) was observed. 
 
Risk factors associated with impaired lung function  
We explored the mutually adjusted associations of three well-known early-life 
respiratory risk factors (preterm birth, maternal smoking during pregnancy, and 
asthma family history), as well as the lifestyle factors at the time of lung function 
testing, BMI and smoking status (former and current smoker) and obstructive and 
restrictive phenotypes as well as FEV1, FVC, and FEV1/FVC ratio z-scores. The 
combined meta-analysis results are illustrated in Table 2 (for spirometry phenotypes) 
and Table E2 (for z-scores) and results additionally adjusted for asthma in Table 3 
and Table E3. 
 
  
Table 2. Meta-analysis results of obstructive and restrictive phenotypes in 







 P for Q 
statistic 
OR 95% CI 
Obstructive phenotype 
Preterm birth 
<10 9 60.8 0.0089 1.82 1.08 to 3.06 
>10 - 15 5 17.6 0.30 2.73 1.67 to 4.46 
>15 - 20 8 6.7 0.38 1.61 1.13 to 2.29 
>20 - 25 4 0.0 0.63 1.37 0.88 to 2.12 





<10 9 0.0 0.61 1.11 0.94 to 1.30 
>10 - 15 6 0.0 0.98 1.20 0.90 to 1.59 
>15 - 20 10 9.1 0.36 1.43 1.14 to 1.78 
>20 - 25 3 0.0 0.41 1.43 1.07 to 1.93 
5 - 25 11 0.0 0.53 1.16 1.01 to 1.35 
Asthma 
family history 
<10 9 26.9 0.20 1.34 1.14 to 1.58 
>10 - 15 6 0.0 0.55 1.39 1.01 to 1.93 
>15 - 20 11 0.0 0.52 1.46 1.24 to 1.72 
>20 - 25 3 29.6 0.24 1.59 1.22 to 2.07 
5 - 25 12 0.0 0.83 1.44 1.25 to 1.66 
BMI 
<10 9 40.6 0.097 1.06 1.02 to 1.10 
>10 - 15 8 55.3 0.022 1.04 1.00 to 1.09 
>15 - 20 12 17.7 0.27 1.05 1.04 to 1.07 
>20 - 25 4 0.0 0.47 1.03 1.01 to 1.05 
5 - 25 13 44.7 0.019 1.05 1.03 to 1.06 
Former 
smoker 
>10 - 15 2 0.0 0.61 0.67 0.45 to 1.01 
>15 - 20 10 28.9 0.18 0.83 0.71 to 0.98 
>20 - 25 4 0.0 0.63 1.37 1.04 to 1.82 
10 - 25 11 41.3 0.048 0.93 0.75 to 1.16 
Current 
smoker 
>10 - 15 2 51.0 0.15 0.88 0.38 to 2.05 
>15 - 20 11 35.5 0.11 1.21 1.01 to 1.44 
>20 - 25 4 0.0 0.70 1.34 1.01 to 1.78 
10 - 25 11 29.8 0.13 1.24 1.05 to 1.46 
Restrictive phenotype 
Preterm birth 
<10 8 0.0 0.79 1.17 0.78 to 1.75 
>10 - 15 5 0.0 0.92 1.46 0.72 to 2.97 
>15 - 20 6 0.0 0.79 1.16 0.72 to 1.87 
>20 - 25 3 0.0 0.87 0.88 0.41 to 1.92 





<10 9 0.0 0.92 0.91 0.73 to 1.14 
>10 - 15 6 0.0 0.95 1.16 0.79 to 1.70 
>15 - 20 9 40.9 0.095 0.98 0.61 to 1.58 
>20 - 25 4 0.0 0.73 0.84 0.52 to 1.36 
5 - 25 11 0.0 0.66 1.00 0.82 to 1.22 
Asthma 
family history 
<10 9 3.8 0.40 0.92 0.74 to 1.15 
>10 - 15 6 0.0 0.97 0.91 0.58 to 1.44 
>15 - 20 10 13.4 0.32 0.89 0.71 to 1.12 
>20 - 25 4 0.0 0.64 0.97 0.66 to 1.42 
5 - 25 12 0.0 0.84 0.96 0.79 to 1.16 
BMI 
<10 9 69.3 0.001 0.88 0.80 to 0.96 
>10 - 15 8 51.6 0.035 0.80 0.75 to 0.85 
>15 - 20 12 78.8 <0.001 0.80 0.75 to 0.85 
>20 - 25 4 92.6 <0.001 0.84 0.70 to 1.00 
5 - 25 13 75.1 <0.001 0.81 0.78 to 0.85 
Former 
smoker 
>10 - 15 2 0.0 0.35 0.65 0.40 to 1.04 
>15 - 20 9 25.3 0.24 0.98 0.79 to 1.21 
>20 - 25 4 56.6 0.075 0.57 0.27 to 1.23 
10 - 25 11 35.9 0.10 0.93 0.76 to 1.12 
Current 
smoker 
>10 - 15 2 62.2 0.10 0.89 0.27 to 2.97 
>15 - 20 11 27.3 0.18 0.80 0.60 to 1.05 
>20 - 25 4 0.0 0.54 0.72 0.48 to 1.06 
10 - 25 11 19.6 0.23 0.85 0.67 to 1.08 
* Model 1 was adjusted for asthma family history, maternal smoking during 




Table 3. Meta-analysis results of obstructive and restrictive phenotypes in 







 P for Q 
statistic 
OR 95% CI 
Obstructive phenotype 
Preterm birth 
<10 8 53.1 0.037 2.04 1.24 to 3.34 
>10 - 15 6 21.0 0.28 2.83 1.73 to 4.46 
>15 - 20 8 7.1 0.38 1.53 1.06 to 2.22 
>20 - 25 4 0.0 0.47 1.49 0.94 to 2.36 





<10 9 0.0 0.70 1.06 0.89 to 1.28 
>10 - 15 6 0.0 0.97 1.28 0.95 to 1.73 
>15 - 20 10 17.0 0.29 1.48 1.20 to 1.82 
>20 - 25 3 0.0 0.79 1.23 0.86 to 1.75 
5 - 25 11 0.0 0.58 1.13 0.97 to 1.33 
Asthma family 
history 
<10 9 21.9 0.25 1.09 0.90 to 1.32 
>10 - 15 6 0.0 0.63 1.17 0.82 to 1.67 
>15 - 20 11 0.0 0.84 1.28 1.07 to 1.52 
>20 - 25 3 69.6 0.037 1.33 0.74 to 2.40 
5 - 25 12 0.0 0.67 1.21 1.04 to 1.41 
BMI 
<10 9 53.7 0.027 1.05 1.00 to 1.11 
>10 - 15 8 0.0 0.50 1.06 1.04 to 1.09 
>15 - 20 12 16.5 0.28 1.04 1.03 to 1.06 
>20 - 25 4 0.0 0.88 1.04 1.01 to 1.07 
5 - 25 13 34.4 0.071 1.04 1.03 to 1.06 
Former smoker 
>10 - 15 2 0.0 0.72 0.67 0.45 to 1.01 
>15 - 20 10 20.8 0.25 0.83 0.70 to 0.97 
>20 - 25 4 0.0 0.59 1.55 1.14 to 2.11 
10 - 25 11 47.0 0.023 0.96 0.76 to 1.22 
Current 
smoker 
>10 - 15 2 54.1 0.14 0.89 0.37 to 2.15 
>15 - 20 11 45.1 0.052 1.18 0.90 to 1.54 
>20 - 25 4 0.0 0.67 1.28 0.92 to 1.79 
10 - 25 11 37.6 0.07 1.18 0.93 to 1.49 
Restrictive phenotype 
Preterm birth 
<10 8 0.0 0.70 1.08 0.68 to 1.73 
>10 - 15 5 0.0 0.85 1.80 0.88 to 3.71 
>15 - 20 6 0.0 0.83 1.17 0.72 to 1.92 
>20 - 25 3 0.0 0.95 0.76 0.30 to 1.92 





<10 9 0.0 0.71 0.95 0.75 to 1.22 
>10 - 15 6 0.0 0.98 1.19 0.78 to 1.79 
>15 - 20 9 43.8 0.076 0.98 0.59 to 1.62 
>20 - 25 4 0.0 0.99 1.01 0.61 to 1.69 
5 - 25 11 0.0 0.59 1.06 0.86 to 1.32 
Asthma family 
history 
<10 9 3.8 0.40 0.99 0.77 to 1.27 
>10 - 15 5 0.0 0.88 0.89 0.54 to 1.46 
>15 - 20 10 25.9 0.21 0.88 0.69 to 1.12 
>20 - 25 4 0.0 0.61 0.99 0.63 to 1.56 
5 - 25 12 0.0 0.84 1.02 0.83 to 1.25 
BMI 
<10 9 75.0 <0.001 0.86 0.77 to 0.95 
>10 - 15 8 50.8 0.039 0.79 0.74 to 0.84 
>15 - 20 12 75.9 <0.001 0.80 0.75 to 0.85 
>20 - 25 4 92.2 <0.001 0.84 0.70 to 1.01 
5 - 25 13 76.9 <0.001 0.81 0.77 to 0.85 
Former smoker 
>10 - 15 2 0.0 0.35 0.64 0.40 to 1.04 
>15 - 20 9 40.3 0.12 0.96 0.77 to 1.20 
>20 - 25 4 46.7 0.13 0.69 0.43 to 1.08 
10 - 25 11 35.2 0.11 0.91 0.75 to 1.11 
Current 
smoker 
>10 - 15 2 62.8 0.10 0.89 0.26 to 3.07 
>15 - 20 11 41.8 0.07 0.74 0.49 to 1.13 
>20 - 25 4 0.0 0.56 0.73 0.47 to 1.15 
10 - 25 11 19.2 0.24 0.87 0.68 to 1.13 
* Model 2 was adjusted for asthma family history, maternal smoking during 
pregnancy, preterm birth, body mass index (BMI) and smoking status, as well as for 
current asthma. 
  
Preterm birth was associated with a higher likelihood of having the obstructive 
phenotype in the <10, >10-15, >15-20, and the overall 5-25 years age groups 
(aOR=1.82, 95% CI: 1.08 to 3.06, aOR=2.73, 95% CI: 1.67 to 4.46; aOR=1.61, 95% 
CI: 1.13 to 2.29 and aOR=1.84, 95% CI: 1.27 to 2.66, Table 2), and effect estimates 
remained similar when current asthma was included in the model (Table 3). 
Maternal smoking during pregnancy was also associated with a higher risk of the 
obstructive phenotype in several age groups, including the overall 5-25 years group 
(aOR=1.16, 95% CI: 1.01 to 1.35), but the effect estimates somewhat attenuated 
when current asthma was adjusted for in the model (Table 3). Asthma family history 
was associated with the obstructive phenotype in model 1, but the effect estimates 
attenuated with additional adjustment for current asthma in model 2 (aOR decreased 
from 1.44 to 1.21). No association between these risk factors and the restrictive 
phenotype was observed. Using spirometry indices as continuous trait outcomes, 
preterm birth was negatively associated with FEV1, FVC, and FEV1/FVC ratio 
z-scores (Table E2). Maternal smoking during pregnancy was negatively associated 
with FEV1 and FEV1/FVC ratio. Asthma family history was negatively associated 
with FEV1 and FEV1/FVC ratio z-scores, but not with FVC z-scores.  
 
BMI was positively associated with the obstructive phenotype in all age groups in 
both models (from aOR=1.03, 95% CI: 1.01 to 1.05 to aOR=1.06, 95% CI: 1.04 to 
1.09 per kg/m
2
 increase, Table 2 and Table 3). In contrast, BMI was negatively 
associated with the restrictive phenotype in all age groups in both models (from 
aOR=0.79, 95% CI: 0.74 to 0.84 to aOR=0.88, 95% CI: 0.80 to 0.96 per kg/m
2
 
increase, Table 2, Table 3, and Figure 4) except in the >20-25 age bin (Figure E6). 
In addition, a higher BMI was associated with higher FEV1 and FVC but lower 
FEV1/FVC ratio z-scores (Table E2). 
 
Current smoking was positively associated with the obstructive phenotype in 
the >15-20, >20-25 and >10-25 years age groups in model 1, but the association 
somewhat attenuated when current asthma was adjusted for in the model (Table 3). 
No clear associations between former smoking and an obstructive phenotype were 
observed in the current study because former making both positively and negatively 
associated with obstructive phenotype. No association between participants’ 
smoking status and the restrictive phenotype was observed. In addition, both former 
and current smoking were associated with higher FVC but lower FEV1/FVC ratio 
z-scores (Table E2). 
 
DISCUSSION 
The main observations in the current study using data from 14 population-based 
cohorts are that: (1) the obstructive and restrictive phenotypes are present at any age 
from childhood to early adulthood without an apparent age trend; and, (2) a diagnosis 
of asthma, family history of asthma, maternal smoking during pregnancy, preterm 
birth, a higher BMI, and current smoking were risk factors for the obstructive 
phenotype, while a lower BMI was the only factor associated with a restrictive 
phenotype in this age range. 
 
Previous studies 
Previous studies have reported that the prevalence of an obstructive spirometric 
phenotype in young adults is between 5 and 7% [21-23]. Our current results extend 
these previous findings by demonstrating that an obstructive phenotype widely 
exists in the general population from childhood to early adulthood. The prevalence 
of the restrictive phenotype during early childhood to young adulthood ranged from 
1.8 to 7.7% in our study. These figures are lower than in population-based studies of 
adults 40 years or older, where prevalence range from around 7 to 20% [5-10]. Most 
participants with obstructive and restrictive phenotypes in our study were classified 
as having mild impairments, and interestingly, no difference in respiratory 
symptoms between participants with the restrictive phenotype and normal lung 
function was observed. As such, they may be at the early stage of the impairment 
and indicate a potential window of opportunity for early interventions to conserve or 
improve their lung function [24]. 
 
Interpretation of key findings 
Several early life potential risk factors, including asthma family history, maternal 
smoking during pregnancy, and preterm birth, were associated with the obstructive 
phenotype. Preterm birth is associated with several respiratory sequelae during early 
childhood, such as bronchopulmonary dysplasia and higher risk of 
lower-respiratory-tract/respiratory syncytial virus infections [25]. Further, preterm 
birth has been associated with substantial impairments in airflow later during 
childhood and adolescence [26, 27]. In the current study, preterm birth was related to 
a higher risk of having an obstructive phenotype and a lower FEV1 z-score up to early 
adulthood. Despite recent substantial advances in neonatal care, with more babies 
surviving after preterm birth (including extreme prematurity, defined as <28 weeks 
gestation), the underlying pathophysiological mechanisms related to future respiratory 
health in these patients need further investigation [28]. 
 
Maternal smoking during pregnancy is a well-known in utero exposure that is 
negatively associated with fetal lung development and respiratory function in 
new-born infants [29] and with a higher risk of recurrent wheezing throughout 
childhood [30, 31]. Our results support these findings by demonstrating that maternal 
smoking during pregnancy is associated with a higher risk of the obstructive 
phenotype and impaired lung function development assessed as FEV1 and FEV1/FVC 
ratio z-scores in offspring.  
  
 
Further, asthma and smoking are other well-known factors associated with airway 
obstruction [32], and children with persistent asthma are at higher risk for fixed 
airflow obstruction and possibly COPD in early adulthood [33, 34]. As expected, 
current asthma was strongly associated with the obstructive phenotype (more than 2 
fold) and lung function impairment (lower FEV1 and FEV1/FVC z-scores) in our 
study. Current smoking of the participants was also associated with a higher 
likelihood of the obstructive phenotype (almost 20%). However, the association 
between current smoking and the obstructive phenotype was attenuated somewhat 
when a current diagnosis of asthma was taken into consideration, and the same trend 
was also observed for asthma family history and maternal smoking during pregnancy, 
suggesting that involved mechanisms partly overlap with asthma pathophysiology. It 
should be noted that we did not consider asthma as a confounder in the regression 
model (Model 2), since asthma and airway obstruction may represent the same disease 
entity, but rather to explore shared risk factors between asthma and our spirometry 
outcomes. However, we acknowledge that not all individuals classified as having 
asthma necessarily have clinical asthma, as the criteria for asthma in young children 
are typically based on symptoms only and not any objective tests. Future studies may 
explore more specific characteristics of asthma, such as airway hyperresponsiveness 
or airway inflammation, in relation to lower lung function development. 
 
We did not identify any association between explored risk factors and the restrictive 
phenotype, except for BMI, where we found a lower BMI to be associated with the 
restrictive phenotype, indicating different underlying metabolic pathobiology between 
the obstructive and restrictive phenotypes. Although restrictive spirometry outcomes 
and lung disease are receiving increased attention in respiratory research lately, most 
studies to date were designed to explore health consequences of restrictive disease [9, 
10, 12], while origins and risk factors remain poorly studied. In adults, early life 
circumstances, such as low birth weight and intrauterine growth restriction [35, 36], 
pneumonia before school age [37], smoking [38], abdominal adiposity [38], and dust 
exposure [39] have been associated with lower FVC levels. In our study, smoking 
status was not associated with the restrictive phenotype, possibly because of the low 
cigarette load among adolescents and young adults. However, we observed a two-way 
relationship between BMI and lung function in our study. On the one hand, a lower 
BMI was associated with increased likelihood of restrictive phenotype and BMI 
correlated negatively with FVC z-scores from childhood to adolescence. On the other 
hand, a higher BMI was associated with increased likelihood of obstructive phenotype 
and correlated negatively with FEV1/FVC ratio z-scores from childhood to young 
adulthood. In children, faster weight growth is associated with higher FVC and FEV1 
values [40]. BMI gain during early childhood has, however, greater influence on lung 
volume than airway growth, which may lead to airway dysanapsis [41, 42]. This is a 
phenomenon where the growth of the lung parenchyma is beyond the caliber of the 
airways leading to a higher FVC than FEV1, and a lower than expected FEV1/FVC 
ratio [43]. Of high clinical relevance is the observation that among obese children 
with asthma, dysanapsis has been associated with severe disease exacerbations [41].  
Lower BMI during early childhood has in other studies been associated with lower 
FVC [42] and restrictive spirometric phenotype [44]. Those results indicate that 
maintenance of normal BMI during childhood to early adulthood may lead to 
improved respiratory health. In addition, the influence of BMI on lung function could 
differ depending on the proportion of different body components (i.e., fat mass and 
lean mass) [45, 46]. Due to lack of body composition data in our study, we cannot 
explore these mechanisms further. 
 
Strengths and Limitations 
Using data from 14 population-based cohorts in Europe, we provide robust estimates 
on the prevalence of obstructive and restrictive phenotypes from childhood to young 
adulthood. However, some limitations of the current study should be noted. Firstly, 
our current study is exploratory. Although three well-known early life risk factors 
and lifestyle factors were taken into account, residual confounding, by e.g., diet or 
physical activity, and unexplored risk factors may still be an issue. Besides, the 
definition of restrictive phenotype in the current study was based on spirometry, 
which is commonly used in population-based studies [9, 10] but was not confirmed 
by residual volume and/or total lung capacity data. While the obstructive disease has 
received much attention in recent years, less is known about factors associated with 
restrictive outcomes. Future studies may explore the association between a 
restrictive phenotype and other early life factors, such as additional perinatal factors 
(including extreme prematurity), growth trajectories, air pollution exposure, 
respiratory insults, and diet [47, 48]. In addition, we did not have the possibility to 
explore potential influence of allergic comorbidities such as atopy, atopic dermatitis 
or allergic rhinitis, as earlier studies have indicated [49, 50]. Secondly, our study 
included almost 50,000 participants from 14 population-based cohorts from Europe, 
which provides high study power and external validity of the results, but also 
introduces some heterogeneity according to the fit of the GLI equation. In order to 
make the results comparable between cohorts, we centered the z-scores in each 
cohort according to the mean values of non-asthmatic, asymptomatic lifelong 
non-smokers [14]. Thirdly, not all cohorts contributed data on all the risk factors, but 
we included all available variables in the regression analysis. In addition, definitions 
in some risk factors slightly differed between cohorts as appears in the appendix. 
 
Conclusions 
Both obstructive and restrictive phenotypes do indeed occur during childhood and 
early adulthood but without a clear age trend. Participants with the obstructive 
phenotype more often reported asthma and wheezing symptoms. In addition, several 
well-known risk factors for airway disease in adults were associated with the 
obstructive phenotype across ages, including asthma family history, preterm birth, 
smoking, and higher BMI, while the only identified factor related to the restrictive 
phenotype was lower BMI, pointing to other reasons for this phenotype in children 
compared to adults. Further studies on the mechanisms of these functional 
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Figure 1. Prevalence of the obstructive (A) and restrictive phenotypes (B) from 
early childhood to young adulthood. The numbers above each bar represent the 
number of cases in the respective study. Cohorts linked by lines had the same mean 




Figure 2. Prevalence of any wheezing in participants with obstructive or restrictive 
phenotypes, or normal lung function. The numbers above each bar represent the 
number of cases in the respective study. Cohorts linked by lines had the same mean 




Figure 3. Meta-analysis results of association between asthma and obstructive 




Figure 4. Meta-analysis results of association between body mass index and 





Online Data Supplement 
 
“Spirometric phenotypes from early childhood to young adulthood – A    CADSET 
(Chronic Airway Disease Early Stratification) study”  
 
Authors: 
Gang Wang; Jenny Hallberg; Dimitrios Charalampopoulos; Maribel Casas Sanahuja; Robab 
Breyer-Kohansal; Arnulf Langhammer; Raquel Granell; Judith M. Vonk; Annemiek Mian; 
Núria Olvera; Lisbeth Mølgaard Laustsen; Eva Rönmark; Alicia Abellan; Alvar Agusti; Syed 
Hasan Arshad; Anna Bergström; H Marike Boezen; Marie-Kathrin Breyer; Otto Burghuber; 
Anneli Clea Bolund; Adnan Custovic; Graham Devereux; Gavin C Donaldson; Liesbeth 
Duijts; Ana Esplugues; Rosa Faner; Ferran Ballester; Judith Garcia-Aymerich; Ulrike 
Gehring; Sadia Haider; Sylvia Hartl; Helena Backman; John W. Holloway; Gerard H. 
Koppelman; Aitana Lertxundi; Turid Lingaas Holmen; Lesley Lowe; Sara M. Mensink-Bout; 
Clare S Murray; Graham Roberts; Linnea Hedman; Vivi Schlünssen; Torben Sigsgaard; 
Angela Simpson; Jordi Sunyer; Maties Torrent; Stephen Turner; Maarten Van den Berge; 
Roel C. H. Vermeulen; Sigrid Anna Aalberg Vikjord; Jadwiga A Wedzicha; Anke H. 




Cohort-specific methods (alphabetical order) .................................................................................. 3 
Cohort-specific acknowledgements (alphabetical order) ............................................................... 17 
Cohort-specific funding statements (alphabetical order) .............................................................. 19 
Tables .............................................................................................................................................. 24 
Figures ............................................................................................................................................. 27 
References ....................................................................................................................................... 33 
 
  
Cohort-specific methods (alphabetical order) 
Avon Longitudinal Study of Parents and Children (ALSPAC) 
Design and study population 
Pregnant women resident in Avon, UK with expected dates of delivery 1st April 1991 to 31st 
December 1992 were invited to take part in the study [1-3]. The initial number of pregnancies 
enrolled is 14,541 (for these at least one questionnaire has been returned or a “Children in 
Focus” clinic had been attended by 19/07/99). Of these initial pregnancies, there was a total of 
14,676 fetuses, resulting in 14,062 live births and 13,988 children who were alive at  1 year of 
age. 
When the oldest children were approximately 7 years of age, an attempt was made to bolster 
the initial sample with eligible cases who had failed to join the study originally. As a result, 
when considering variables collected from the age of seven onwards (and potentially 
abstracted from obstetric notes) there are data available for more than the 14,541 pregnancies 
mentioned above. The number of new pregnancies not in the initial sample (known as Phase I 
enrolment) that are currently represented on the built files and reflecting enrolment status at 
the age of 24 is 913 (456, 262 and 195 recruited during Phases II, III and IV respectively), 
resulting in an additional 913 children being enrolled. The phases of enrolment are described 
in more detail in the cohort profile paper and its update. The total sample size for analyses 
using any data collected after the age of seven is therefore 15,454 pregnancies, resulting in 
15,589 fetuses. Of these 14,901 were alive at 1 year of age.  
A 10% sample of the ALSPAC cohort, known as the Children in Focus (CiF) group, attended 
clinics at the University of Bristol at various time intervals between 4 to 61 months of age. 
The CiF group were chosen at random from the last 6 months of ALSPAC births (1432 
families attended at least one clinic). Excluded were those mothers who had moved out of the 
area or were lost to follow-up, and those partaking in another study of infant development in 
Avon. 
Please note that the study website contains details of all the data that is available through a 
fully searchable data dictionary and variable search tool" and reference the following 
webpage: http://www.bristol.ac.uk/alspac/researchers/our-data/ 
Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committees. Informed consent for the use of data collected via 
questionnaires and clinics was obtained from participants following the recommendations of 
the ALSPAC Ethics and Law Committee at the time. 
Definitions of potential confounders and covariates 
Premature birth was defined as babies who were delivered before 37 completed weeks of 
gestation.  
Maternal smoking during pregnancy was defined as self-reported active tobacco smoking 
during any trimester of pregnancy.  
Asthma family history was defined as combined self-reported maternal and paternal asthma 
ever.  
Smoking exposure during childhood at 8 years was defined as mother reported child in a 
smoky room during weekdays/weekends. Smoking status at 15 and 24 years were defined as 
self-reported active smoking from questionnaires and clinics.  
Asthma at 8 (mother reported), 15 (self-reported) and 24 (self-reported) years was defined as 
doctor diagnosis ever.  
Asthma in the last 12 months at 8 (mother reported), 15 (self-reported) and 24 (self-reported) 
years was defined as doctor diagnosis ever and (current symptoms or medication).  
Current wheeze at 8 (mother reported), 15 (self-reported) and 24 (self-reported) was defined 
as wheezing in the last 12 months. 
Data at 24 years was collected and managed using REDCap electronic data capture tools [4]  
hosted at University of Bristol. REDCap (Research Electronic Data Capture) is a secure, web-
based software platform designed to support data capture for research studies. 
 
Children (Barn), Allergy, Milieu, Stockholm, Epidemiology (BAMSE) 
Design and study population 
BAMSE (Children, Allergy, Milieu, Stockholm, Epidemiology in Swedish) is a prospective 
population-based cohort study of children recruited at birth and followed during childhood 
and early adulthood. Details of the study design, inclusion criteria, enrolment and data 
collection are described elsewhere [5]. Between February 1994 and November 1996, 4089 
infants from inner-city, urban and suburban districts of Stockholm were included in the cohort. 
Data on background characteristics, respiratory health, and exposure factors were obtained 
from parental questionnaires administered at age of 2 months. Follow-up questionnaires were 
repeatedly answered by parents at age of 1, 2, 4, 8, 12, and 16 years. The response rates were 
96%, 94%, 91%, 84%, 82% and 78%, respectively. At the 24-year follow-up, questionnaires 
focusing on respiratory symptoms and key exposures such as smoking habits were answered 
by the participants themselves. Details about the definitions of health outcomes and covariates 
are provided in the online supplement. 
Definitions of potential confounders and covariates 
Premature birth was defined as babies who were delivered before 37 completed weeks of 
gestation. 
Maternal smoking during pregnancy was defined as the mother smoked at least one cigarette 
per day at any point in time during pregnancy. 
Asthma family history was defined as any parent with a doctor‟s diagnosis of asthma and 
asthma medication of mother or father at the time of questionnaire 0. 
Parental smoking during childhood was defined as any of the parents smoking ≥1 cigarette 
per day at each visit time point. 
Smoking status were defined as positive answers to the question related to smoke: 1) Yes, 
sometimes or 2) Yes, every day. 
Asthma was defined as ever been diagnosed asthma by a doctor at all follow-up time (8, 16 
and 24 years). 
Asthma in the last 12 months was defined if at least two of the following three criteria were 
fulfilled: doctor‟s diagnosis of asthma ever; wheezing in the last 12 months; and/or use of 
asthma medication during the last 12 months. 





Design and study population 
The Generation R Study is a population-based prospective cohort study from fetal life until 
adulthood conducted in the Netherlands, Rotterdam [6]. The study is designed to identify 
early environmental and genetic causes, and causal pathways leading to normal and abnormal 
growth, development and health from fetal life, childhood and young adulthood. In total, 
9,778 mothers with a delivery date from April 2002 until January 2006 were enrolled. Of 
these mothers 9,749 gave birth to live born children. Response at baseline was 61%, and 
general follow-up rates until the age of 13 years were around 80%. Data collection in children 
and their parents includes questionnaires, interviews, detailed physical and ultrasound 
examinations, behavioral observations, lung function, Magnetic Resonance Imaging and 
biological sampling.  For the current project, the total number of subjects was 4,738 and 3,869 
at age 9 and 13 years, respectively. Information on maternal ethnicity, preterm birth, maternal 
smoking during pregnancy, and parental asthma was obtained by self-reported questionnaires 
during pregnancy, and midwife or hospital registries. Child height and weight were measured 
without shoes and heavy clothing, and in standing position at the research center. Information 
on wheezing and asthma of the child was obtained by questions adapted from the 
International Study on Asthma and Allergy in Childhood (ISAAC) questionnaires. Lung 
function at the ages of 9 and 13 years of the child was measured by spirometry according to 
ATS/ERS guidelines. 
Definitions of potential confounders and covariates 
Categories of ethnicity were created based on country of births of parents according to 
Statistics Netherlands into the Global Lung Function Initiative categories of ethnicity. 
Premature birth was defined as birth before 37 weeks of gestational age. 
Maternal smoking during pregnancy was defined as ever maternal smoking in pregnancy. 
Parental asthma was defined as maternal or paternal history of asthma.  
Body mass index (BMI) was calculated based on measured height and weight  
Ever asthma was categorized based on the question: “Has your child ever had asthma 
diagnosed by a doctor? (no; yes)”  
Current asthma was defined by means of the MeDALL criteria: 2 out of 3 of the following 
questions: Has your child ever been diagnosed with asthma by a doctor? or/and Has your 
child suffered from a wheezing chest in these past 12 months? or/and Has your child received 
prescribed medication for asthma symptoms in the past 12 months? 
Any wheeze in the last 12 months was categorized based on the question: “Has your child 
suffered from attacks of wheezing in the chest in the past 12 months? (no; yes)”  
More than 3 episodes of wheeze in the last 12 months were categorized based on the question: 
“Has your child suffered from attacks of wheezing in the chest in the past 12 months?” 
(No/Yes, less than 4 attacks/Yes, 4 or more attacks) 
Current maternal smoking during childhood at age 9 years categorized based on the question: 
“Have you ever smoked? (No; yes, but stopped; yes, I still do) “ 
 
Trøndelag Health Study (HUNT) 
Design and study population 
The Trøndelag Health Study (HUNT) is a population-based study having invited all 
inhabitants aged 13- 104 years living in the Nord-Trøndelag region to participate in 
questionnaires, interviews and clinical measurement in four data collections from 1984 to 
2019. In 2019 questionnaire data also were collected from the Sør-Trøndelag region, 
including 104.000 participants (40% of invited) [7]. 
In Nord-Trøndelag, HUNT invited persons aged 20 + in 1984-86 (HUNT1), 1995-97 
(HUNT2), 2006-08 (HUNT3) and 2017-19 (HUNT4), while corresponding data collections 
from adolescents aged 13-19 years were performed in Young-HUNT1 (1995-97), Young-
HUNT3 (2006-08) and YoungHUNT4 (2017-19). The adults were invited to field stations 
located in all municipalities, while Young-HUNT performed data collection at schools. In the 
four HUNT studies number of participants (% of invited) have been, 77,000 (89%), 65,000 
(69%), 51,000 (54%) and 56,000 (54%) in HUNT1, 2, 3 and 4, respectively. In Young-HUNT 
9000 (88%), 8200 (78%), and 8000 (76%) participated in Young-HUNT 1,3 and 4, 
respectively. Among all participants in YoungHUNT1 and 3, and samples of participants in 
the adult part of  HUNT (11-15000 persons) were included in spirometry[8]. 
  
Definitions of potential confounders and covariates 
Smoking status was defined based on answers to question on:  never-smoking, previous 
smoking, current daily or occasional smoking. 
Asthma was defined as ever been diagnosed asthma by a doctor. 
Any wheeze was defined as: any wheeze or dyspnoea in the last 12 months prior to the visit 
data. 
 
INfancia y Medio Ambiente – Environment and Childhood (INMA) 
Design and study population 
INMA (INfancia y Medio Ambiente – Environment and Childhood; 
http://www.proyectoinma.org) is a prospective population-based birth cohort study in several 
regions of Spain: Gipuzkoa, Menorca, Sabadell, and Valencia. This project aims to study the 
associations between pre- and postnatal environmental exposures and growth, health, and 
development from early fetal life until adolescence and has been described previously in 
detail [9]. Pregnant women recruitment took place between 1997 and 1998 in Menorca and 
between 2003 and 2008 in Gipuzkoa, Sabadell, and Valencia. Inclusion criteria were as 
follows: to be at least 16 years old, to have intention to deliver in the reference hospital, to 
have a singleton pregnancy, not have any assisted conception, and not have any 
communication problems. Children have been followed from birth until 12 years in Gipuzkoa, 
Sabadell, and Valencia and until 18 years in Menorca. Data on sociodemographic 
characteristics, lifestyle factors, and respiratory symptoms was obtained from mothers during 
pregnancy and in each follow-up of the child. Informed consent was obtained from all 
participants and the study was approved by the Hospital Ethics Committees in each 
participating region. 
Definitions of potential confounders and covariates 
Premature birth was defined as less than 37 weeks of gestational age. 
Maternal smoking during pregnancy …  
Asthma family history was defined as maternal history of allergic asthma, allergic rhinitis or 
eczema. 
Parental smoking during childhood was defined … 
Smoking status… 
Asthma was defined as ever been diagnosed asthma by a doctor at all follow-up times.  
Any wheeze was defined as at least 1 episode of wheeze in the last 12 months prior to the visit 
data. … 
 
Isle of Wight (IoW) 
Design and study population 
IOW is an unselected birth cohort study established in 1989 on the Isle of Wight, UK [10-12].  
After the exclusion of adoptions, perinatal deaths, and refusal for follow-up, written informed 
consent was obtained from parents to enrol 1,456 newborns born between 1st January 1989 
and 28th February 1990.  Follow-up assessments were conducted to 26 years of age to 
prospectively study the development of asthma and allergic diseases. At each follow-up, 
validated questionnaires were completed by the parents. Additionally, the Skin Prick Test 
(SPT) was performed on 980, 1036 and 853 participants at 4, 10 and 18 years of age to check 
allergic reactions to common allergens. At 10, 18, and 26 years, spirometry and methacholine 
challenge tests were performed to diagnose lung problems. Ethics approvals were obtained 
from the Isle of Wight Local Research Ethics Committee (now named the National Research 
Ethics Service, NRES Committee South Central – Southampton B) at recruitment and for the 
subsequent follow-ups. 
Definitions of potential confounders and covariates 
Asthma was defined as “yes” to “have you ever had asthma?”  
Asthma in the last 12 months was defined as “yes” to “have you ever had asthma?” and either 
of “have you had wheezing in the last 12 months”? or “have you had current asthma 
treatment?”.  
Any wheeze was defined as at least 1 episode of wheeze in the last 12 months. Number of 
wheeze attacks was defined as 1-3, 4-12, >12 wheeze attacks in the last 12 months.  
Asthma family history was defined as any parent with diagnosis of asthma of mother or father 
at the time of questionnaire. 
Premature birth was defined as babies who were delivered before 37 completed weeks of 
gestation.  
Maternal smoking during pregnancy was defined as the mother smoking at least one cigarette 
per day at the time of recruitment (i.e. a few days after giving birth while inpatient).  
Smoking status was defined as positive answer to the question “Do you currently smoke”.  
Parental smoking during childhood was defined as any of the parents smoking ≥1 cigarette 
per day inside the house at each follow-up. 
 
 
Lung, hEart, sociAl, boDy (LEAD) 
Design and study population 
The Austrian (Lung, hEart, sociAl, boDy) LEAD Study (NCT01727518) is a single-centered, 
longitudinal, observational, population-based cohort study aiming to investigate the 
relationship between genetic, environmental, social, developmental and ageing factors 
influencing respiratory health and co-morbidities through life. In total, 11,423 male and 
female, aged 6–80 years have been recruited randomly from the national inhabitants register 
stratified by age, gender and residential area from Vienna (urban population) and Lower 
Austria (rural population). Study population participated and completed their first visit from 
2012-2016 including main measurements and questionnaires described in detail elsewhere 
[13]. 
Definitions of potential confounders and covariates 
Asthma was a current “doctor`s diagnosis of Asthma” . 
Wheezing was defined as “wheezing in sudden attacks and/or wheezing without cold”. 
Asthma family history was defined as any parent with doctor`s diagnosis of asthma of mother 
and/or father ever. 
Premature birth was defined as birth <260 days of gestation and/or birth weight or <2500g . 
Maternal smoking during pregnancy was defined as the mother smoking regularly during 
pregnancy. 
Parental smoking during childhood was defined as any of the parents smoked regularly during 
childhood. 
Current smoking was defined as reported smoking regularly. 
 
Lifelines 
Design and study population 
LifeLines [14], population base study Since all inhabitants in The Netherlands are registered 
with a general practitioner (GP), eligible participants were invited to participate in the 
LifeLines Cohort Study through their GP. A large number of GPs within the northern three 
provinces of The Netherlands (Friesland, Groningen and Drenthe) were involved and invited 
all their patients between the ages of 25 and 50 years, unless the participating GP considered 
the patient not eligible based on the following criteria: severe psychiatric or physical illness;  
limited life expectancy (<5 years); insufficient knowledge of the Dutch language to complete 
a Dutch questionnaire. Subsequently, individuals who were interested to participate received 
detailed information by mail about the LifeLines Cohort Study, and an informed consent form. 
After the signed informed consent was received by the LifeLines organization, the 
participants received a baseline questionnaire and an invitation to a comprehensive health 
assessment at the LifeLines research site. During the visit, participants were asked to indicate 
whether their family members, such as partners, parents, parents-in-law and children would 
also be willing to participate in the study. If so, permission was asked to send them an 
invitation to participate. Children could only participate if one of their parents was a 
participant. In addition, inhabitants of the northern provinces could also register themselves 
via the LifeLines website. Aged between 25 and 50 and living in the 3 northern provinces of 
The Netherlands (Friesland, Groningen, Drenthe). Of these included subjects the children, 
partners, and parents were also invited (could be any age). Subjects had to master Dutch so 
that they could complete the questionnaire and understand the instructions during the visit.  
severe psychiatric or physical illness, limited life expectancy (<5 years), insufficient 
knowledge of the Dutch language to complete a Dutch questionnaire. 
  
Definitions of potential confounders and covariates 
Premature birth was defined as babies who were delivered before 37 completed weeks of 
gestation. 
Maternal smoking during pregnancy was self-reported in the questionnaires. Positive answers 
were considered if they reported that the mother smoked less or as usual during pregnancy. 
Asthma family history was defined as any parent with a doctor‟s diagnosis of asthma at the 
baseline visit.  
Parental smoking during childhood was defined as any of the parents smoked regularly during 
childhood in the self-reported question. 
Smoking status were defined as positive answers to the question related to smoke, excluding 
recent starters, ex-smokers who smoked less than a year, current/ex-smokers without 
information on duration. 
Asthma was defined as ever been diagnosed asthma by a doctor at the baseline visit. .  
Asthma in the last 12 months was not defined in Lifelines cohort. 
Any wheeze ever was defined as positive answer in the self-reported question: “Have you 
ever suffered from wheezing?” 
 
Manchester Asthma and Allergy Study (MAAS) 
Design and study population 
MAAS is an unselected birth cohort study established in 1995 in Manchester, UK [15].   It 
consists of a mixed urban-rural population within 50 square miles of South Manchester and 
Cheshire, United Kingdom located within the maternity catchment area of Wythenshawe and 
Stepping Hill Hospitals.  All pregnant women were screened for eligibility at antenatal visits 
(8-10th week of pregnancy). Of the 1499 couples who met the inclusion criteria (≤10 weeks 
of pregnancy, maternal age ≥18 years, and questionnaire and skin prick data test available for 
both parents), 288 declined to take part in the study and 27 were lost to follow-up between 
recruitment and the birth of a child. A total of 1184 children were born into the study between 
February 1996 and April 1998. They were followed prospectively for 19 years to date and 
attended follow-up clinics for assessments, which included lung function measurements, skin 
prick testing, biological samples (serum, plasma and urine), and questionnaire data collection. 
The study was approved by the North West – Greater Manchester East Research Ethics 
Committee. 
Definitions of potential confounders and covariates 
Preterm birth was defined as babies who were delivered before 37 completed weeks of 
gestation.  
Maternal smoking during pregnancy was defined as the mother smoking at recruitment.  
Parental smoking status was defined as maternal and/or paternal current smoking at each 
follow-up.  
Asthma family history was defined as any parent with a doctor‟s diagnosis of asthma at 
recruitment.  
Asthma was defined as ever being diagnosed with asthma by a doctor at all follow-up times.  
Current wheeze was defined wheezing or whistling in the chest in the last 12 months. Number 
of wheeze attacks was defined as 1-3, 4-12, >12 wheeze attacks in the last 12 months.   
Current asthma medication is defined as the use of medicines, pills, puffers or other 
medication for wheezing or asthma in the last 12 months. 
 
Obstructive Lung Disease in Northern Sweden (OLIN) 
Design and study population 
The OLIN (Obstructive Lung Disease in Northern Sweden) studies is an epidemiological 
research programme about asthma, allergy, chronic obstructive pulmonary disease (COPD) 
ongoing since 1985. In 2006, the second OLIN-paediatric cohort was recruited, consisting of 
a prospective population-based cohort of schoolchildren followed through childhood and 
adolescence. All 2704 children in first and second grade (median age 8 years) in three 
municipalities in Norrbotten, Sweden were invited to a parental questionnaire and n=2585 
participated (97% of invited). The study design has been described in detail elsewhere [16]. 
The questionnaire included the International Study of Asthma and Allergy among children 
(ISAAC) core questions and additional questions about respiratory symptoms, family history, 
physician-diagnoses and treatment of asthma, rhinitis and eczema as well as background 
characteristics and exposures. The cohort was followed-up by a parental questionnaire at age 
12 years, and by self-completed questionnaires at age 15 and 19 years of age. At age 19 years, 
the children in two of the municipalities were invited to clinical examinations including 
spirometry and n=1470 participated.  
Definitions of potential confounders and covariates 
Maternal smoking during pregnancy was defined as an affirmative answer to the question 
“Did the mother smoke during pregnancy?” 
Asthma family history was defined as mother or father having asthma. 
BMI was calculated based on height and weight measured at the follow-up at age 19 years.  
Smoking status was based on the question “Are you a non-smoker, former smoker or current 
smoker?” in the follow-up at age 19 years. 
Asthma was defined as an affirmative answer to the question “Have you been diagnosed by a 
physician as having asthma?” 
Any wheeze in the last 12 months was defined as an affirmative answer to the question “Have 
you had wheezing or whistling in the chest in the last 12 months?”  
 
Prevention and Incidence of Asthma and Mite Allergy (PIAMA)   
Design and study population 
PIAMA (Prevention and Incidence of Asthma and Mite Allergy) is an ongoing birth cohort 
study.  Details of the study design have been published previously [17, 18]. In brief, pregnant 
women were recruited from the general population through antenatal clinics in the north, west 
and center of the Netherlands in 1996-1997. The baseline study population consisted of 3963 
newborns. Questionnaires were completed by the parents during pregnancy, when the child 
was 3 months old, and then annually from 1 up to 8 years; at ages 11, 14 and 17 years, 
questionnaires were completed by the parents as well as the participants themselves. Data 
were obtained on child and family characteristics, a wide range of environmental and lifestyle 
exposures and on asthma and other allergic and respiratory outcomes. Lung function was 
measured at age 8-, 12-, and 16-years using spirometry. The Medical Ethical Committees of 
the participating institutes approved the study, and written informed consent was obtained 
from all parents or legal guardians.  
Definitions of potential confounders and covariates 
Premature birth was defined as babies who were delivered before 37 completed weeks of 
gestation. 
Maternal smoking during pregnancy was defined as the mother smoked at least during the 
first 4 weeks of pregnancy. 
Asthma family history was defined as any parent with a doctor‟s diagnosis of asthma. 
Passive smoking during childhood was defined as any person smoking ≥1 cigarette per week 
in the house at each visit time point. 
Current smoking status was defined as any current smoking regardless of frequency. 
Asthma was defined as ever been diagnosed asthma by a doctor at each visit time point. 
Asthma in the last 12 months was defined if a child has a doctor‟s diagnosis of asthma ever 
and wheezing or shortness of breath in the last 12 months and use of asthma medication in the 
last 12 months. 




Design and study population 
SEATON is an unselected birth cohort study established in 1997 in Aberdeen, UK, which was 
designed to explore the relationship between antenatal dietary exposures and asthma 
outcomes in childhood [19].  2000 healthy pregnant women attending an antenatal clinic, at 
median 12 weeks gestation, were recruited. An interviewer administered a questionnaire to 
the women and atopic status was ascertained by skin prick test (SPT). The cohort included 
1924 children born between April 1998 and December 1999. Participants were recruited 
prenatally and followed up by self−completion questionnaire to 15 years of age using postal 
questionnaires to record the presence of asthma and allergic diseases. Lung function 
measurements and SPT to common allergens was performed at 5, 10 and 15 years. The study 
was approved by the North of Scotland Research Ethics Committee. 
Definitions of potential confounders and covariates 
Preterm birth was defined as babies who were delivered before 37 completed weeks of 
gestation.  
Maternal smoking during pregnancy was defined as the mother smoking at recruitment. 
Parental smoking status was not available.  
Asthma heredity was defined as any parent with asthma at recruitment. Asthma was defined 
as asthma ever confirmed by a doctor at all follow-up times.  
Current wheeze was defined wheezing in the chest in the last 12 months.  
Number of wheeze attacks was defined as 1-3, 4-12, >12 wheeze attacks in the last 12 months.  
 
SUS 
Design and study population 
SUS contains a cross-sectional and a longitudinal study of young farmers and, as controls, a 
group of male army recruits. The cohort was established during the period February 1992 to 
February 1994 and consisted of 1,734 male and 230 female farming students. Additionally, 
407 randomly chosen army recruits served as controls. At baseline, data on demographics, 
respiratory health, and exposure characteristics were collected. The participation rate was 79% 
among the farming students and 61% among the army recruits. For five years, the participants 
were followed with annual questionnaires and phone interviews. A comprehensive follow-up 
was done in 2007 tracking new addresses, deaths, and emigration by use of the Danish Civil 
Registration System. At this follow-up, 1170 participants were re-examined, representing an 
overall attrition rate of 51.7%. Further information on the cohort can be found elsewhere [20]. 
Definitions of potential confounders and covariates 
Asthma was defined as self-reported, doctor diagnosed asthma. 
Parental asthma heredity was defined as reported asthma among one or both parents. 
Any wheeze was defined as ever being bothered by wheeze without having a cold. 
Smoking status was classified in three groups. Smoking status was defined as “Never” if the 
person reported to never have smoked one or more cigarettes a day in a period longer than 14 
days and to not be a current smoker. Smoking status was defined as “Former” if the person 
reported to have smoked one or more cigarettes a day in a period longer than 14 days, but not 
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Table E1. The definitions of spirometry phenotypes and severity. 
Spirometric 
phenotypes  
Definition  Subgroups  Severity grading 
Normal  
FEV1/FVC z-score >= -1.65 




FEV1/FVC z-score >= -1.65 
AND FVC z-score < -1.65 
Mild  -2 ≤ FVC z-score < -1.65 
Moderate  -3 ≤ FVC z-score < -2 
Severe  FVC z-score < -3 
Obstructive 
phenotype 
FEV1/FVC z-score < -1.65 
Very mild FEV1 z-score ≥ -1.65 
Mild  -2 ≤ FEV1 z-score < -1.65 
Moderate  -3 ≤ FEV1 z-score < -2 




Table E2. Meta-analysis results of z-scores in different age groups.* 
Variables Age groups Number 
of cohorts 
I2 P for Q 
statistic 
OR 95% CI 
FEV1 z-score       
  Preterm birth 
<10 9 28.5 0.19 -0.22 -0.29 to -0.15 
>10 - 15 6 0.0 0.71 -0.15 -0.25 to -0.04 
>15 - 20 9 0.0 0.74 -0.10 -0.20 to -0.0037 
>20 - 25 4 0.0 0.90 -0.048 -0.15 to 0.051 
5 - 25 10 18.2 0.26 -0.16 -0.23 to -0.10 
  Maternal 
smoking during 
pregnancy 
<10 9 0.0 0.90 -0.056 -0.095 to -0.018 
>10 - 15 6 26.3 0.23 -0.068 -0.13 to -0.003 
>15 - 20 11 17.8 0.27 -0.086 -0.13 to -0.04 
>20 - 25 4 0.0 0.73 -0.044 -0.10 to 0.016 
5 - 25 12 0.0 0.47 -0.088 -0.12 to -0.054 
  Asthma family 
history 
<10 9 0.0 0.90 -0.056 -0.095 to -0.018 
>10 - 15 6 26.3 0.23 -0.068 -0.13 to -0.003 
>15 - 20 11 17.8 0.27 -0.086 -0.13 to -0.04 
>20 - 25 4 0.0 0.73 -0.044 -0.10 to 0.016 
5 - 25 12 0.0 0.47 -0.088 -0.12 to -0.054 
  BMI 
<10 9 70.3 <0.001 0.05 0.035 to 0.064 
>10 - 15 8 90.0 <0.001 0.064 0.046 to 0.082 
>15 - 20 12 99.8 <0.001 0.093 -0.012 to 0.20 
>20 - 25 4 98.1 <0.001 0.028 -0.006 to 0.063 
5 - 25 13 99.8 <0.001 0.088 0.023 to 0.15 
  Former 
smoker 
>10 - 15 2 0.0 0.78 -0.018 -0.15 to 0.11 
>15 - 20 10 11.0 0.34 -0.036 -0.077 to 0.0064 
>20 - 25 4 0.5 0.39 0.12 0.058 to 0.18 
10 - 25 11 51.8 0.01 0.014 -0.044 to 0.073 
  Current 
smoker 
>10 - 15 2 60.9 0.11 0.041 -0.25 to 0.34 
>15 - 20 11 0.0 0.59 -0.0046 -0.045 to 0.036 
>20 - 25 4 66.5 0.03 0.061 -0.044 to 0.17 
10 - 25 11 40.6 0.052 0.025 -0.024 to 0.073 
FVC z-score       
  Preterm birth 
<10 9 28.8 0.19 -0.11 -0.19 to -0.043 
>10 - 15 6 0.0 0.95 -0.076 -0.18 to 0.026 
>15 - 20 9 0.0 0.93 0.031 -0.063 to 0.12 
>20 - 25 4 0.0 0.88 0.031 -0.067 to 0.13 
5 - 25 10 0.0 0.52 -0.061 -0.12 to -0.0015 
  Maternal 
smoking during 
pregnancy 
<10 9 23.7 0.23 0.0096 -0.023 to 0.042 
>10 - 15 6 50.8 0.058 -0.018 -0.11 to 0.07 
>15 - 20 10 28.2 0.19 0.049 -0.007 to 0.11 
>20 - 25 4 0.0 0.78 0.08 0.016 to 0.14 
5 - 25 11 27.0 0.16 0.015 -0.015 to 0.044 
  Asthma family 
history 
<10 9 0.0 0.94 0.019 -0.019 to 0.058 
>10 - 15 6 0.0 0.53 0.027 -0.037 to 0.091 
>15 - 20 11 0.0 0.71 0.015 -0.029 to 0.059 
>20 - 25 4 0.0 0.91 0.041 -0.016 to 0.097 
5 - 25 12 0.0 0.94 0.0049 -0.028 to 0.038 
  BMI 
<10 9 65.1 0.0034 0.07 0.057 to 0.083 
>10 - 15 8 97.4 <0.001 0.096 0.062 to 0.13 
>15 - 20 12 97.6 <0.001 0.086 0.064 to 0.11 
>20 - 25 4 99.2 <0.001 0.064 0.012 to 0.12 
5 - 25 13 98.1 <0.001 0.099 0.077 to 0.12 
  Former 
smoker 
>10 - 15 2 0.0 0.91 0.043 -0.081 to 0.17 
>15 - 20 10 0.0 0.62 0.038 -0.0033 to 0.078 
>20 - 25 4 63.4 0.042 0.11 0.0062 to 0.22 
10 - 25 11 34.2 0.095 0.062 0.015 to 0.11 
  Current 
smoker 
>10 - 15 2 53.1 0.14 0.11 -0.15 to 0.37 
>15 - 20 11 26.4 0.19 0.082 0.043 to 0.12 
>20 - 25 4 0.0 0.52 0.16 0.11 to 0.22 
10 - 25 11 36.6 0.077 0.11 0.064 to 0.15 
FEV1/FVC z-
score 
      
  Preterm birth 
<10 9 54.2 0.026 -0.12 -0.24 to 0.0051 
>10 - 15 6 0.0 0.58 -0.12 -0.22 to -0.016 
>15 - 20 9 37.8 0.12 -0.21 -0.31 to -0.11 
>20 - 25 4 0.0 0.90 -0.13 -0.23 to -0.032 
5 - 25 10 27.0 0.17 -0.16 -0.22 to -0.10 
  Maternal 
smoking during 
pregnancy 
<10 9 26.3 0.21 -0.066 -0.10 to -0.031 
>10 - 15 6 0.0 0.98 -0.093 -0.14 to -0.045 
>15 - 20 10 0.0 0.82 -0.13 -0.19 to -0.07 
>20 - 25 4 10.0 0.34 -0.14 -0.21 to -0.074 
5 - 25 11 23.0 0.20 -0.074 -0.11 to -0.042 
  Asthma family 
history 
<10 9 0.0 0.68 -0.13 -0.17 to -0.085 
>10 - 15 6 0.0 0.59 -0.15 -0.21 to -0.084 
>15 - 20 11 0.0 0.88 -0.17 -0.21 to -0.12 
>20 - 25 4 60.3 0.056 -0.13 -0.24 to -0.02 
5 - 25 12 0.0 0.56 -0.14 -0.18 to -0.11 
  BMI 
<10 9 65.8 0.0029 -0.04 -0.052 to -0.028 
>10 - 15 8 96.3 <0.001 -0.056 -0.084 to -0.028 
>15 - 20 12 87.3 <0.001 -0.055 -0.068 to -0.043 
>20 - 25 4 98.0 <0.001 -0.066 -0.11 to -0.026 
5 - 25 13 95.9 <0.001 -0.064 -0.08 to -0.049 
  Former 
smoker 
>10 - 15 2 0.0 0.53 -0.086 -0.21 to 0.035 
>15 - 20 10 13.9 0.31 -0.12 -0.17 to -0.083 
>20 - 25 4 51.5 0.10 -0.026 -0.12 to 0.071 
10 - 25 11 43.7 0.036 -0.075 -0.13 to -0.021 
  Current 
smoker 
>10 - 15 2 0.0 1.00 -0.09 -0.24 to 0.055 
>15 - 20 11 54.8 0.015 -0.13 -0.20 to -0.066 
>20 - 25 4 76.4 0.0053 -0.15 -0.28 to -0.03 
10 - 25 11 60.2 0.0014 -0.13 -0.19 to -0.074 
* Model was adjusted for asthma family history, maternal smoking during pregnancy, 







Figure E1. The GLI fit of FEV1 (A), FVC (B) and FEV1/FVC ratio (C) in each cohorts and 
time points. Cohorts linked by lines had the same mean age (in years).  
 
Figure E2. The associations between the cohort-specific prevalence of obstructive (A) and 
restrictive (B) phenotypes and age.  
 
Figure E3. The prevalence of ever been diagnosed with asthma in participants with 
obstructive or restrictive phenotype, or normal lung function. The numbers above each bar 
represent the number of cases in the respective study. Cohorts linked by lines had the same 
mean age (in years). 
  
 
Figure E4. Meta-analysis results of association between asthma and obstructive phenotype in 
different age bins (A = age <10, B = age >10-15, C = age >15-20, and D = age >20-25). 
  
 
Figure E5. Meta-analysis results of association between asthma and restrictive phenotype in 
different age bins (A = age <10, B = age >10-15, C = age >15-20, D = age >20-25, and E = 
age 5-25 years).  
 
Figure E6. Meta-analysis results of association between body mass index and restrictive 
phenotype in Model 2 in different age bins (A = age <10, B = age >10-15, C = age >15-20, 
and D = age >20-25).   
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